Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Express Scripts
Cipla
Deloitte
Healthtrust
Farmers Insurance
Daiichi Sankyo
Dow
Cerilliant

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,964,592

« Back to Dashboard

Which drugs does patent 7,964,592 protect, and when does it expire?


Patent 7,964,592 protects ZYKADIA and is included in one NDA.

This patent has seventy-four patent family members in thirty-five countries.

Summary for Patent: 7,964,592

Title:2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Abstract: Novel pyrimidine derivatives of formula I ##STR00001## to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Inventor(s): Garcia-Echeverria; Carlos (Basel, CH), Kanazawa; Takanori (Tsukuba, JP), Kawahara; Eiji (Tsukuba, JP), Masuya; Keiichi (Tsukuba, JP), Matsuura; Naoko (Tsukuba, JP), Miyake; Takahiro (Tsukuba, JP), Ohmori; Osamu (Tsukuba, JP), Umemura; Ichiro (Tsukuba, JP)
Assignee: Novartis AG (Basel, CH)
Application Number:10/549,250
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,964,592

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0305929.2Mar 14, 2003
United Kingdom0319227.5Aug 15, 2003
United Kingdom0322370.8Sep 24, 2003
PCT Information
PCT FiledMarch 12, 2004PCT Application Number:PCT/EP2004/002616
PCT Publication Date:September 23, 2004PCT Publication Number: WO2004/080980

Non-Orange Book Patents for Patent: 7,964,592

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,893,0742, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders► Subscribe
8,263,590Pyrimidine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,964,592

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2006107785► Subscribe
Portugal2287156► Subscribe
Portugal2275413► Subscribe
Portugal1660458► Subscribe
Portugal1606265► Subscribe
Poland1660458► Subscribe
Peru03722005► Subscribe
New Zealand585188► Subscribe
New Zealand542219► Subscribe
Norway333306► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Citi
Federal Trade Commission
Accenture
Farmers Insurance
Queensland Health
QuintilesIMS
Cerilliant
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot